BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SHR-4394 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SHR-4394\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06783829-11101@assetmemo.bio
DTSTAMP:20261121T004552Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:SHR-4394: Phase 1 readout est. (NCT06783829)
DESCRIPTION:SHR-4394\, phase 1\, Prostate Cancer.\nStudy: A Study of SHR-43
 94 Injection in Subjects With Prostate Cancer\nEstimated primary completio
 n: March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/shr-43
 94#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6783829
URL:https://assetmemo.bio/drug/shr-4394#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407283-11101@assetmemo.bio
DTSTAMP:20261121T004552Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:SHR-4394: Phase 1/2 readout est. (NCT07407283)
DESCRIPTION:SHR-4394\, phase 1/2\, Prostate Cancer.\nStudy: A Clinical Stud
 y of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer\nE
 stimated primary completion: November 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/shr-4394#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07407283
URL:https://assetmemo.bio/drug/shr-4394#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
